Navigation Links
Novira Therapeutics Expands Management Team with Appointment of Klaus Klumpp, Ph.D., the Former Global Head of Roche's Virology Discovery Initiatives, as Vice President Discovery Research
Date:6/5/2013

DOYLESTOWN, Pa., June 5, 2013 /PRNewswire/ -- Novira Therapeutics Inc., today announced the expansion of its senior management team with the appointment of Klaus Klumpp , Ph.D., as vice president, discovery research. Dr. Klumpp will build an internal virology team focused on the hepatitis B virus (HBV) and will oversee biology research at Novira.

"The addition of Klaus is an important step in the growth of our company as we transition from a discovery stage company into a development stage company," said Osvaldo Flores , Ph.D., president and chief scientific officer of Novira. "We are excited to welcome Klaus to our team. His expertise and outstanding record of accomplishments in antiviral drug discovery and clinical development further strengthen Novira's capabilities. Dr. Klumpp will be instrumental in our efforts to build a world class virology team, develop powerful tools to characterize mechanisms of HBV persistence and to develop innovative drugs that can cure chronic HBV infection."

Prior to joining Novira, Dr. Klumpp led research and development activities for more than 15 years at Roche, including leadership of teams at the company's locations in Welwyn Garden City, U.K., Palo Alto, Calif., and most recently Nutley, N.J. At the New Jersey site, he was vice president and global head of virology discovery.

Dr. Klumpp has an established track record of successful research and development activities that has involved collaborations with other companies and academic laboratories. He was responsible for the discovery and transition into clinical development of a number of new leads and drug candidates for the treatment of acute and chronic viral diseases, including influenza, hepatitis C, HBV, Dengue and HIV. In addition, he supported the clinical development of antiviral drugs such as Tamiflu for the treatment and prophylaxis of influenza virus infection and Balapiravir, Mericitabine and Danoprevir, new antiviral agents for the treatment of HCV infection.

Dr. Klumpp received a doctorate in virology from work performed at the Wellcome Research Laboratories, Beckenham, Kent, U.K ., at the European Molecular Biology Laboratories (EMBL), Heidelberg, Germany, and  at the EMBL in Grenoble, France. He holds a diploma degree in biology from the Technical University Darmstadt, Germany.

About Novira Therapeutics
Novira Therapeutics is focused on the discovery of first-in-class antiviral therapeutics for the treatment of chronic HBV infection, a global disease with a high level of unmet medical need. Novira's oral drugs target the core protein of the virus and offer a promising treatment option both as monotherapy and in combination with current standards of care. The company's antivirals potentially address limitations in treating chronic HBV infection, a disease for which the only class of oral drugs available, polymerase inhibitors, is rarely curative despite lifelong treatment.

For more information, visit www.noviratherapeutics.com.

Contacts:

Corporate Contact
Osvaldo Flores , Ph.D.
President, CSO
lflores@noviratherapeutics.com

Media Contacts
David Schull                      
Matt Middleman, M.D.                                 
Russo Partners                                        
T: 212-845-4271                              
T: (212) 845-4272
david.schull@russopartnersllc.com
matt.middleman@russopartnersllc.com


'/>"/>
SOURCE Novira Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
2. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
3. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
4. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
5. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
6. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
7. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
8. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
9. Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant
10. Zenobia Therapeutics, Inc. And BioBlocks, Inc. Announce Sale Of A Joint Fragment Library Ideal For Screening By All Popular Methods
11. New Forecast Shows Global Protein Therapeutics Market to Reach $143.4 Billion by 2015
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
(Date:6/23/2016)... , June 23, 2016 Research and ... News Issue 52" report to their offering. ... influenza treatment creates a favourable commercial environment for MedImmune to ... patient base that will serve to drive considerable growth for ... would serve to cap sales considerably, but development is still ...
(Date:6/23/2016)... and INDIANAPOLIS , June 23, ... a Lilly Diabetes Tomorrow,s Leaders Scholarship is any indication, ... winners, announced today online at www.diabetesscholars.org by ... 1 diabetes stand in the way of academic and ... the Foundation,s scholarship program since 2012, and continues to ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is ... a fitness app. The fitness app plans to fix the two major problems leading the ... one size fits all type program , They don’t eliminate all the reasons ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the ... several important health care topics including advance care planning, healthcare costs and patient ...
(Date:6/25/2016)... ... ... temporary closing of Bruton Memorial Library on June 21 due to a possible lice infestation, ... aspect of head lice: the parasite’s ability to live away from a human host, and ... necessary one in the event that lice have simply gotten out of control. , As ...
(Date:6/25/2016)... ... 25, 2016 , ... First Choice Emergency Room , the largest network ... the Medical Director of its new Mesquite-Samuell Farm facility. , “We are pleased ... location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. ...
(Date:6/25/2016)... , ... June 25, 2016 , ... ... and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a ... area —Johnson is one of the first doctors to perform the treatment. Orthobiologics ...
Breaking Medicine News(10 mins):